Ideaya (IDYA) announced the appointment of Stu Dorman as chief commercial officer. Dorman has over 20 years of oncology and hematology experience. Prior to joining Ideaya, Dorman was the VP, U.S. oncology business unit head at Gilead Science (GILD).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences nominates IDE034 as development candidate, exercises option
- Biocytogen announces Ideaya’s nomination of development candidate IDE034
- Dollar Tree downgraded, eBay upgraded: Wall Street’s top analyst calls
- Leerinks downgrades Ideaya Biosciences pending clarity on key programs
- Ideaya Biosciences downgraded to Market Perform from Outperform at Leerink